Mast Cells in Mammary Carcinogenesis: Host or Tumor Supporters?

doi:10.21873/anticanres.11411

Cited by 9 publications

(5 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The relationship between MC density of tumors, the progression of angiogenesis, and tumor development may highlight the possible role of MCs in tumor biology. Therefore, the possibility of targeting MC activation [67,68], inhibiting the release of mediators using c-Kit receptor tyrosine kinase inhibitors (TKI) (including imatinib, masitinib [69]), or using tryptase inhibitors (mainly gabexate mesylate and nafamostat mesylate, both inhibitors of trypsin-like serine proteases [69,70]) may be valuable therapeutic approaches to control the tumor development [71]. Masitinib, a TKI that targets c-kit receptors (CD117), has been used in veterinary medicine for years, and lately, human clinical trials were initiated to test its clinical efficacy as single or add-on treatment human cancers such as mastocytosis, gastrointestinal stromal tumors (NCT00998751), colon cancer (NCT03556956), prostate cancer (NCT03761225), and pancreatic cancer (NCT03766295) [72].…”

Section: Mcs As Therapeutic Targetsmentioning

confidence: 99%

Role of Mast Cells in Shaping the Tumor Microenvironment

Komi

Redegeld

2019

Clinic Rev Allerg Immunol

253

181

View full text Add to dashboard Cite

Early mast cell (MC) infiltration has been reported in a wide range of human and animal tumors particularly malignant melanoma and breast and colorectal cancer. The consequences of their presence in the tumor microenvironment (TME) or at their margins still remain unclear as it is associated with a good or poor prognosis based on the type and anatomical site of the tumor. Within the tumor, MC interactions occur with infiltrated immune cells, tumor cells, and extracellular matrix (ECM) through direct cell-tocell interactions or release of a broad range of mediators capable of remodeling the TME. MCs actively contribute to angiogenesis and induce neovascularization by releasing the classical proangiogenic factors including VEGF, FGF-2, PDGF, and IL-6, and nonclassical proangiogenic factors mainly proteases including tryptase and chymase. MCs support tumor invasiveness by releasing a broad range of matrix metalloproteinases (MMPs). MC presence within the tumor gained additional significance when it was assumed that controlling its activation by tyrosine kinase inhibitors (imatinib and masitinib) and tryptase inhibitors (gabexate and nafamostat mesylate) or controlling their interactions with other cell types may have therapeutic benefit.

show abstract

Section: Mcs As Therapeutic Targetsmentioning

confidence: 99%

Role of Mast Cells in Shaping the Tumor Microenvironment

Komi

Redegeld

2019

Clinic Rev Allerg Immunol

253

181

View full text Add to dashboard Cite

show abstract

“…Many studies showed that the transduction activities induced by histamine receptors include a variety of intracellular signaling pathways [18]. Interestingly, the expression of histamine receptors has been detected in many tumor cells, making them sensitive to histamine stimulation and contributing to tumor development [6]. Here, we compared the expression of different histamine receptors between normal skin tissues and AIDS-KS tissues by using IHC staining.…”

Section: Resultsmentioning

confidence: 99%

“…Histamine is mainly produced and released by mast cells (MCs), acting as a bivalent regulator for cancer development [6]. Histamine, together with its receptors, plays an important role in various allergic diseases by regulating different inflammation and immune responses [7].…”

Section: Introductionmentioning

confidence: 99%

Role of Histamine and Related Signaling in Kaposi’s Sarcoma-Associated Herpesvirus Pathogenesis and Oncogenesis

Chen

Song

Plaisance-Bonstaff

et al. 2023

Viruses

View full text Add to dashboard Cite

Although Kaposi’s sarcoma-associated herpesvirus (KSHV) has been reported to cause several human cancers including Kaposi’s sarcoma (KS) and primary effusion lymphoma (PEL), the mechanisms of KSHV-induced tumorigenesis, especially virus–host interaction network, are still not completely understood, which therefore hinders the development of effective therapies. Histamine, together with its receptors, plays an important role in various allergic diseases by regulating different inflammation and immune responses. Our previous data showed that antagonists targeting histamine receptors effectively repressed KSHV lytic replication. In the current study, we determined that histamine treatment increased cell proliferation and anchorage-independent growth abilities of KSHV-infected cells. Furthermore, histamine treatment affected the expression of some inflammatory factors from KSHV-infected cells. For clinical relevance, several histamine receptors were highly expressed in AIDS-KS tissues when compared to normal skin tissues. We determined that histamine treatment promoted KSHV-infected lymphoma progression in immunocompromised mice models. Therefore, besides viral replication, our data indicate that the histamine and related signaling are also involved in other functions of KSHV pathogenesis and oncogenesis.

show abstract

“…These findings may form the basis for a further evaluation of the clinical usefulness of histone methyltransferase inhibition for the treatment of conditions characterized by mast cell transformation, such as mastocytosis. We can also foresee the use of methyltransferase inhibition in malignant conditions where mast cells might have a pathogenic impact (46).…”

Section: Discussionmentioning

confidence: 99%